AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11838820 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (short-term, placebo-controlled study)
Number of subjects: 0
Study 11838820 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (extended open-label maintenance)
Number of subjects: 0
Study 11838820 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo-controlled discontinuation study)
Number of subjects: 0
Study 30361113 — intervention group
Group type: EXPERIMENTAL
Intervention: RM12 (12 cmH2O PEEP)
Number of subjects: 30
Study 30361113 — intervention group
Group type: EXPERIMENTAL
Intervention: RM17 (17 cmH2O PEEP)
Number of subjects: 30
Study 30361113 — intervention group
Group type: EXPERIMENTAL
Intervention: RM7 (7 cmH2O PEEP)
Number of subjects: 30
Study 30361113 — intervention group
Group type: COMPARATOR
Intervention: Control (7 cmH2O PEEP)
Number of subjects: 30
Study 28853975 — intervention group
Group type: EXPERIMENTAL
Intervention: website educational program only (n = 281)
Number of subjects: 917
Study 28853975 — intervention group
Group type: EXPERIMENTAL
Intervention: website plus face to face lesson (n = 302)
Number of subjects: 917
Study 28853975 — intervention group
Group type: COMPARATOR
Intervention: no intervention (n = 334)
Number of subjects: 917
Study 27461787 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (4.0 mL buccal infiltration)
Number of subjects: 100
Study 27461787 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (4.0 mL buccal infiltration)
Number of subjects: 100
Study 27461787 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 100
Study 27461787 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 100
Study 25361785 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training group (REHACOP)
Number of subjects: 42
Study 25361785 — intervention group
Group type: COMPARATOR
Intervention: Control group (occupational activities)
Number of subjects: 42
Study 22549509 — intervention group
Group type: EXPERIMENTAL
Intervention: 930 mg/d choline intake
Number of subjects: 2
Study 22549509 — intervention group
Group type: COMPARATOR
Intervention: 480 mg/d choline intake
Number of subjects: 2
Study 20386478 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration training (VG)
Number of subjects: 31
Study 20386478 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 31
Study 17683643 — intervention group
Group type: EXPERIMENTAL
Intervention: Litebook LED treatment device (1,350 lux white light, spectral peaks at 464 nm and 564 nm) for 30 minutes a day upon awakening and prior to 8 A.M.
Number of subjects: 26
Study 17683643 — intervention group
Group type: COMPARATOR
Intervention: Inactivated negative ion generator (control) for 30 minutes a day upon awakening and prior to 8 A.M.
Number of subjects: 26
Study 17683643 — intervention group
Group type: EXPERIMENTAL
Intervention: Litebook LED treatment device
Number of subjects: 26
Study 17683643 — intervention group
Group type: COMPARATOR
Intervention: Inactivated negative ion generator (control)
Number of subjects: 26
Study 16295262 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11926786 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of sildenafil plus inhaled iloprost
Number of subjects: 30
Study 11926786 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg of sildenafil plus inhaled iloprost
Number of subjects: 30
Study 11926786 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost alone
Number of subjects: 30
Study 11926786 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of sildenafil
Number of subjects: 30
Study 11926786 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg of sildenafil
Number of subjects: 30
Study 11926786 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide
Number of subjects: 30
Study 11926786 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of sildenafil plus iloprost
Number of subjects: 30
Study 9788422 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 Gy preoperative irradiation
Number of subjects: 100
Study 9788422 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID (Voltaren resinat 2 x 75 mg/day for 2 weeks)
Number of subjects: 100
Study 9788422 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (no prophylactic therapy)
Number of subjects: 100
Study 7649965 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement in drug research
Number of subjects: 63
Study 2758840 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy and Yoon ring
Number of subjects: 91
Study 2758840 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy and Yoon ring
Number of subjects: 91
Study 2758840 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy and Pomeroy
Number of subjects: 91
Study 2758840 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 91
Study 1159592 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy
Number of subjects: 0
Study 1159592 — intervention group
Group type: COMPARATOR
Intervention: Exchange transfusion
Number of subjects: 0
Study 31490864 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic teaching
Number of subjects: 0
Study 31490864 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontextual active learning
Number of subjects: 0
Study 31490864 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CRM education)
Number of subjects: 0
Study 29330975 — intervention group
Group type: EXPERIMENTAL
Intervention: Desarda technique
Number of subjects: 186
Study 29330975 — intervention group
Group type: COMPARATOR
Intervention: Darning technique
Number of subjects: 186
Study 26122922 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent to extended follow-up (10 years)
Number of subjects: 1921
Study 26122922 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic status at baseline
Number of subjects: 1921
Study 26122922 — intervention group
Group type: COMPARATOR
Intervention: Smoking status at follow-up
Number of subjects: 1921
Study 26122922 — intervention group
Group type: COMPARATOR
Intervention: Hypertension status at follow-up
Number of subjects: 1921
Study 26122922 — intervention group
Group type: COMPARATOR
Intervention: Dyslipidemia status at follow-up
Number of subjects: 1921
Study 26122922 — intervention group
Group type: COMPARATOR
Intervention: Mean number of years in study at time of consent
Number of subjects: 1921
Study 26122922 — intervention group
Group type: COMPARATOR
Intervention: Site enrollment size
Number of subjects: 1921
Study 26122922 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds of consenting based on age
Number of subjects: 1921
Study 26122922 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds of consenting based on symptomatic status
Number of subjects: 1921
Study 26122922 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds of consenting based on smoking status
Number of subjects: 1921
Study 26122922 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds of consenting based on duration in study
Number of subjects: 1921
Study 26122922 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds of consenting based on site enrollment size
Number of subjects: 1921
Study 26122922 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds of consenting based on dyslipidemia status
Number of subjects: 1921
Study 23708162 — intervention group
Group type: EXPERIMENTAL
Intervention: Undiagnosed diabetes
Number of subjects: 8795
Study 23708162 — intervention group
Group type: EXPERIMENTAL
Intervention: Known diabetes
Number of subjects: 8795
Study 23708162 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 8795
Study 23708162 — intervention group
Group type: COMPARATOR
Intervention: Normal
Number of subjects: 8795
Study 22340054 — intervention group
Group type: EXPERIMENTAL
Intervention: LCAF + C group (late accelerated hyperfractionated radiotherapy combined with capecitabine)
Number of subjects: 168
Study 22340054 — intervention group
Group type: EXPERIMENTAL
Intervention: LCAF group (late accelerated hyperfractionated conformal radiotherapy)
Number of subjects: 168
Study 22340054 — intervention group
Group type: COMPARATOR
Intervention: CF group (radiotherapy alone)
Number of subjects: 168
Study 19930729 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication techniques intervention
Number of subjects: 0
Study 16510747 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary-vein ablation
Number of subjects: 146
Study 16510747 — intervention group
Group type: COMPARATOR
Intervention: Control group (amiodarone and two cardioversions)
Number of subjects: 146
Study 15228261 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg of leishmanial protein in the alum-precipitated ALM + BCG vaccine mixture
Number of subjects: 24
Study 15228261 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg of leishmanial protein in the alum-precipitated ALM + BCG vaccine mixture
Number of subjects: 24
Study 15228261 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg of leishmanial protein in the alum-precipitated ALM + BCG vaccine mixture
Number of subjects: 24
Study 15228261 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg of leishmanial protein in the alum-precipitated ALM + BCG vaccine mixture
Number of subjects: 24
Study 15228261 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum-precipitated ALM + BCG vaccine mixture
Number of subjects: 24
Study 10528416 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction pump
Number of subjects: 60
Study 10528416 — intervention group
Group type: COMPARATOR
Intervention: Redon bottle
Number of subjects: 60
Study 9074719 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (1,250 IU x 2/SC/day for 30 days)
Number of subjects: 20
Study 1680616 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adrenergic blockade)
Number of subjects: 18
Study 1680616 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockade with propranolol
Number of subjects: 18
Study 1680616 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-adrenergic blockade with phentolamine
Number of subjects: 18
Study 6350097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 1200 mg daily
Number of subjects: 138
Study 6350097 — intervention group
Group type: COMPARATOR
Intervention: Antacid (Mylanta II, 7 oz daily)
Number of subjects: 138
Study 28141666 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with a history of breast cancer
Number of subjects: 969
Study 28141666 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy lifestyle behaviors
Number of subjects: 969
Study 28141666 — intervention group
Group type: COMPARATOR
Intervention: Women without a history of breast cancer
Number of subjects: 969
Study 27267255 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow velocity reserve (CFVR) measured by transthoracic Doppler echocardiography
Number of subjects: 86
Study 27267255 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow velocity reserve (CFVR)
Number of subjects: 86
Study 23965751 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma knife radiosurgery (GKRS)
Number of subjects: 52
Study 23965751 — intervention group
Group type: COMPARATOR
Intervention: Repeated transsphenoidal adenomectomy (TSA)
Number of subjects: 52
Study 22442079 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches combined with paired associative stimulation (PAS)
Number of subjects: 12
Study 22442079 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches combined with transcranial direct current stimulation (tDCS)
Number of subjects: 12
Study 22442079 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches combined with paired associative stimulation (PAS)
Number of subjects: 12
Study 22442079 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches combined with transcranial direct current stimulation (tDCS)
Number of subjects: 12
Study 19383242 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated diclofenac 50 mg, administered orally three times daily for 2 weeks prior to surgery
Number of subjects: 51
Study 19383242 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg, administered orally three times daily for 2 weeks prior to surgery
Number of subjects: 51
Study 19383242 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered orally three times daily for 2 weeks prior to surgery
Number of subjects: 51
Study 17440419 — intervention group
Group type: EXPERIMENTAL
Intervention: HFO-TGI (combined high-frequency oscillation and tracheal gas insufflation)
Number of subjects: 14
Study 17440419 — intervention group
Group type: EXPERIMENTAL
Intervention: HFO-TGI
Number of subjects: 14
Study 17440419 — intervention group
Group type: COMPARATOR
Intervention: HFO
Number of subjects: 14
Study 15852464 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of caffeine
Number of subjects: 0
Study 15852464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15852464 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study 12411832 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐beta‐CIT‐FE PET scans with statistical parametric mapping (SPM) analysis
Number of subjects: 16
Study 12411832 — intervention group
Group type: COMPARATOR
Intervention: C‐beta‐CIT‐FE PET scans
Number of subjects: 16
Study 9573535 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest tertile (UProt < 1.9 g/24 hr)
Number of subjects: 352
Study 9573535 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle tertile (UProt 2.0 to 3.8 g/24 hr)
Number of subjects: 352
Study 9573535 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile (UProt 3.9 to 18.8 g/24 hr)
Number of subjects: 352
Study 9573535 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with highest proteinuria and blood pressure
Number of subjects: 352
Study 8159037 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen 200 mg twice daily
Number of subjects: 803
Study 8159037 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 300 mg thrice daily plus dipyridamole 75 mg thrice daily
Number of subjects: 803
Study 3121710 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt‐PA) 80 mg over 3 h
Number of subjects: 290
Study 3121710 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase 1.5 million units over 1 h
Number of subjects: 290
Study 30901755 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured postoperative rehabilitation (SPT)
Number of subjects: 202
Study 30901755 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative approach (SA)
Number of subjects: 202
Study 30901755 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SPT and SA)
Number of subjects: 202
Study 27564924 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilingual/bicultural lay health educator (LHE) education over 3 months
Number of subjects: 329
Study 27564924 — intervention group
Group type: COMPARATOR
Intervention: Education regarding nutrition and physical activity delivered by a health educator
Number of subjects: 329
Study 26343601 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin (8-24 mg/day)
Number of subjects: 261
Study 26343601 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (2-6 mg/day)
Number of subjects: 261
Study 24302188 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone nasal spray (FNS) with amoxicillin, one puff twice daily for 14 days
Number of subjects: 100
Study 24302188 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 80 to 100 mg/kg/day for 14 days
Number of subjects: 100
Study 24302188 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone nasal spray (FNS) with amoxicillin
Number of subjects: 100
Study 21459951 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized rheumatology nurse (SRN)
Number of subjects: 193
Study 21459951 — intervention group
Group type: COMPARATOR
Intervention: Rheumatologist-led diagnostic consult (usual care, UC)
Number of subjects: 193
Study 19478464 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepcidin-20
Number of subjects: 12
Study 19478464 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepcidin-25
Number of subjects: 12
Study 19478464 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepcidin-20 and Hepcidin-25
Number of subjects: 12
Study 17492413 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection followed by early intravesical application of a chemotherapeutic agent
Number of subjects: 0
Study 17492413 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical cystectomy
Number of subjects: 0
Study 17492413 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ-sparing treatment due to combined therapeutic concepts
Number of subjects: 0
Study 17492413 — intervention group
Group type: EXPERIMENTAL
Intervention: New chemotherapeutic agents
Number of subjects: 0
Study 15536108 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine, 10 mg
Number of subjects: 1991
Study 15536108 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril, 20 mg
Number of subjects: 1991
Study 15536108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1991
Study 15536108 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine vs Placebo
Number of subjects: 1991
Study 15536108 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril vs Amlodipine
Number of subjects: 1991
Study 15536108 — intervention group
Group type: COMPARATOR
Intervention: IVUS Atherosclerosis Progression
Number of subjects: 1991
Study 11327189 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative feedback intervention pamphlet
Number of subjects: 697
Study 11327189 — intervention group
Group type: COMPARATOR
Intervention: Control group (no normative feedback)
Number of subjects: 697
Study 9216528 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel
Number of subjects: 318
Study 9216528 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.05% gel
Number of subjects: 318
Study 9216528 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 318
Study 7967692 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling at empirical point Shengen
Number of subjects: 101
Study 7967692 — intervention group
Group type: COMPARATOR
Intervention: Control group (38 cases)
Number of subjects: 101
Study 3118453 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral phenoxymethylpenicillin 2 g every 8 h, reduced to 1 g every 8 h after normalization of temperature.
Number of subjects: 69
Study 3118453 — intervention group
Group type: COMPARATOR
Intervention: Intravenous benzylpenicillin 3 g every 8 h, reduced to oral phenoxymethylpenicillin 1 g every 8 h after normalization of temperature.
Number of subjects: 69
Study 2746447 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% monohydrogen‐monopotassium oxalate (MO)
Number of subjects: 17
Study 2746447 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% dipotassium oxalate (DO) followed by 3% MO
Number of subjects: 17
Study 2746447 — intervention group
Group type: COMPARATOR
Intervention: Distilled water followed by 30% DO
Number of subjects: 17
Study 2746447 — intervention group
Group type: COMPARATOR
Intervention: Distilled water followed by 3% MO
Number of subjects: 17
Study 2746447 — intervention group
Group type: COMPARATOR
Intervention: Distilled water only
Number of subjects: 17
Study 31504461 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive periodontal treatment (IPT; sub- and supragingival scaling/chlorhexidine; n=50)
Number of subjects: 101
Study 31504461 — intervention group
Group type: COMPARATOR
Intervention: Control periodontal treatment (CPT; supragingival scaling; n=51)
Number of subjects: 101
Study 27533954 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blood pressure variability (BPV < median)
Number of subjects: 261
Study 27533954 — intervention group
Group type: COMPARATOR
Intervention: High blood pressure variability (BPV ≥ median)
Number of subjects: 261
Study 25995537 — intervention group
Group type: EXPERIMENTAL
Intervention: Swiss ball exercises
Number of subjects: 20
Study 25995537 — intervention group
Group type: COMPARATOR
Intervention: Mat exercises
Number of subjects: 20
Study 23430159 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 233
Study 23430159 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 233
Study 23430159 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 233
Study 23430159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 20947211 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil
Number of subjects: 66
Study 20947211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 18797408 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 305
Study 18797408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 17214926 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 14758306 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive CD-ROM training
Number of subjects: 12
Study 14758306 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-the-trainer classroom instruction
Number of subjects: 12
Study 14758306 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study 11329461 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of IgG bands of 25, 22, and/or 69 kDa
Number of subjects: 152
Study 11329461 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC stage C
Number of subjects: 152
Study 11329461 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 152
Study 9447532 — intervention group
Group type: EXPERIMENTAL
Intervention: Survanta
Number of subjects: 203
Study 9447532 — intervention group
Group type: COMPARATOR
Intervention: Exosurf
Number of subjects: 203
Study 7960981 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective irradiation after wide local excision of lesions > or = 1.5 mm thick, or Clark's level IV‐V (n = 79)
Number of subjects: 174
Study 7960981 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive irradiation after excision of primary lesions plus limited neck dissection (n = 32)
Number of subjects: 174
Study 7960981 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation after neck dissection for nodal relapse (n = 63)
Number of subjects: 174